All Posts Tagged With: "DNA"
It Could Get Worse Before It Gets Better
There is no way to sugar coat it or paint a rosy picture. This week could be disastrous for the market. Coming off eight straight down trading days, and the largest weekly percentage drop in the history of the Dow, the economic calendar provides no relief.
The Best Way to Buy Into the Biotech Boom
There’s a merger boom going on right now, but amid all the gloom, no one’s really paying much attention.
Global Investing Roundups Thursday, August 14th, 2008
Deere Misses Estimates; Genentech Rejects Roche Bid; Crude Rises on Inventory Report; China Fire & Security an Earnings Inferno; Joining Forces to Battle Insider Trading; Best Buy’s Coup; Merrill Slashes Wall St. Ratings; Ford’s European Makeover
Great Bargains in Ignored Biotech
There has been a lot of strong recommendations around biotech lately on Contrarian Profits.
Phase 1 Investor editor Rob Fannon recently wrote that biotech was one of the few market sectors to show positive returns as many other stocks were getting hammered. He sees great values in the sector.
There’s a good reason for this strength. A struggling economy won’t hurt biotech and medical as much as, say, an automaker, retailer, or restaurant chain… And biotech is one of the few industries showing solid sales growth.
Why the Smart Money Is in Biotech Stocks
As investors plowed into financial and housing stocks in the last few years, they forgot about the pharmaceutical industry, says Jim Nelson in Penny Sleuth.
But now that the party is over, biotech stocks are coming back in a big way. According to mutual-fund research firm Lipper, two biotech funds were amongst the top five best-performing vehicles in July - a dramatic reversal from June when commodities funds were leading the charge.
Big Pharma is buying up promising biotech companies in an effort to boost profit margins. This creates great opportunities for investors, and it’ only just the beginning…
Second Quarter GDP Release Set to Confirm or Deny U.S. Recessionary Fears
A hectic week on the economic calendar is highlighted by the initial look at second quarter gross domestic product (GDP). Remember, a recession is defined as two consecutive quarters of negative growth, so doomsayers have targeted this week’s release as confirmation of their pessimism.
Biotech Sector Could Jump 25% on Roche-Genentech Deal
Swiss drug company Roche (OTC:RHHBY) may not get its hands on San Francisco-based biotech outfit Genenetech (NYSE:DNA) as quickly as it had hoped.
Genetech has formed a special committee of independent directors to evaluate the $89-a-share acquisition offer from Roche, which already owns 56 percent of the US biotech firm.
If the deal does go through it may be bad news for Roche and Genentech shareholders, according to Phase 1 Investor editor Rob Fannon in The Growth Stock Wire. But it would be good news for the biotech industry as a whole…
While I believe the bid is a bad move for Roche – and not a great proposal for Genentech shareholders – this mega-deal is actually good for the entire biotech industry… and its investors.
With Genentech gone, the top of the biotech food chain is empty. Many investors will be searching for new spots to park their biotech cash. And sector valuations are on the rise. Both major biotech indexes – the Nasdaq Biotech Index and AMEX Biotech Index – are up more than 7% in just a few weeks.
Small-cap biotechs are cheap right now. So I’d be willing to bet the sector could jump 25% or more in the coming months. And big-cap names like Biogen (NASDAQ:BIIB), Genzyme (NASDAQ:GENZ), and Elan (NYSE:ELN) have jumped to the top of Big Pharma’s short list of buyout candidates.
If you’re thinking of dabbling in the biotech sector, Roche’s bid for Genentech just may be the buy signal you’re waiting for.
Source: The Buy Signal You’ve Waited For
Switzerland’s Roche Makes $43.7 Billion Offer for U.S. Biotech Pioneer Genentech
A Significant Week for the Market
Here’s a quick heads up from Christian Hill at Investor’s Daily Edge on economic and earnings data due this week…
What Hedge-Fund Managers are Reading This Morning
Last May, shares of Regeneron Pharmaceuticals (REGN), a billion-dollar biotech, slid 35% in just 30 days. The company had no press releases, no earnings reports, nothing.
Latest News
- It Could Get Worse Before It Gets Better3:42pm CDT
- Base Metals Savaged3:36pm CDT
- Crude Plummets Below $803:31pm CDT
- Shortages, Bankruptcy and More!3:28pm CDT
- US Dollar Whipping Everyone3:26pm CDT
- Fed Floods the Markets with US$3:22pm CDT
- Gold Endures Frightful Selloff3:19pm CDT
- Citigroup Concedes Wachovia to Wells Fargo3:00pm CDT
- Breaking News: Dow Rebounds… Biggest One-Day Gain Ever…2:20pm CDT
- Adam Lass Says US Blue Chips Could Lose Another 34%1:49pm CDT
- Why Smart Investors Should Be Thinking about Cows11:42am CDT
- Why Energy and Resource Plays Will Profit in the Long Term10:41am CDT
- Some Very Healthy Resource Stocks Are ‘Shockingly’ Cheap10:20am CDT
- How to Play the Sovereign Wealth Fund Property Boom9:26am CDT
- Early Indicators: Europe Acts to Rescue Banks… Stocks Up…9:19am CDT
- Nouriel Roubini: Markets Will Fall Another 20%5:55pm CDT
- Goerge Soros: Financial Crisis Is the ‘End of an Era’1:48pm CDT
- Government Rescues Will Trigger a Bull Market in Gold11:22am CDT
- Natural Gas and Water Are the Investments of the Future2:41pm CDT
